Dr. Michael Javaheri, MD

Dr. Javaheri practices at CHA Hollywood Presbyterian Medical Center in Los Angeles, California, part of CHA Health Systems.

Dr. Javaheri's NPI, 1124298575, was assigned on February 29, 2008. Dr. Javaheri graduated from Keck School of Medicine of USC in 2003. Dr. Javaheri's California license number on file is A94767.

Dr. Javaheri's primary practice is CHA Hollywood Presbyterian Medical Center, at 1300 N Vermont Ave, Los Angeles, CA 90027 in Los Angeles County. The practice phone is (213) 413-3000.

Dr. Javaheri's primary practice is CHA Hollywood Presbyterian Medical Center in Los Angeles, California, part of CHA Health Systems. Dmand AI also links Dr. Javaheri to 4 medical groups, 2 group practices and clinics and 1 breast imaging center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Javaheri practices, 4 sites in all. Vendor and product names are available with a free account.

Retina specialist is Dr. Javaheri's primary specialty in the NPI Registry, under taxonomy code 207WX0107X. Dr. Javaheri is board certified in ophthalmology by the American Board of Ophthalmology. Dr. Javaheri has a license on file in California.

Dmand AI lists age-related macular degeneration, cataract, conjunctivitis, dry eye, eye infection or inflammation, eyelid inflammation, glaucoma and hereditary corneal conditions among the conditions Dr. Javaheri treats.

CMS data shows 61,984 Medicare services from Dr. Javaheri across 25 procedure codes in 2024, for 1,001 Medicare patients. Medicare paid $4,226,004 for them.

CMS counts 1,001 Medicare patients who saw Dr. Javaheri in 2024. The largest group is 75 to 84, with 425 patients. 75% of them have high cholesterol, and 69% have high blood pressure. 9% are also on Medicaid. Their average risk score is 1.20, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Javaheri's median patient age at 65, with 53% women.

In 2024, Dr. Javaheri wrote 486 Medicare Part D claims for 109 patients. 37% of them were for generic drugs. CMS names the drug for 384 of them, across 13 drugs with 11 or more claims each, at $76,925 in total drug cost. In 2023, CMS named 373 claims across 11 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Javaheri for performance year 2024, reported individually. Dr. Javaheri accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 7 papers to Dr. Javaheri. The most frequent topics are Angiogenesis Inhibitors, Double-Blind Method and Intravitreal Injections. Dr. Javaheri's most frequent co-authors are Rahul Khurana, MD, Rizwan A. Bhatti, MD and Dean Eliott, MD.

Dmand AI links Dr. Javaheri to 1 clinical trial. 1 is still active or recruiting. Open Payments lists research payments to Dr. Javaheri that name 2 trials.

CMS Open Payments shows 754 general payments to Dr. Javaheri from 39 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 59% of the total. Regeneron Pharmaceuticals, Inc. paid the most, $416,328. It also lists 32 research payments totaling $17,186 from 2020 to 2025, naming 2 clinical trials.

Dmand AI lists 3 awards for Dr. Javaheri, most recently CMS Stage 1 EHR in 2014.

Dr. Javaheri graduated from Keck School of Medicine of USC in 2003. Dr. Javaheri is a member of AAO and ASRS.

Dr. Javaheri is in network with 13 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 11. Check the plan with the practice before a visit.